Pricing Reforms Prompt Canadian Business Rethink
Roche Has Withdrawn Tecentriq From HTA Processes
The R&D based pharmaceutical industry would welcome changes to guidelines that will operationalize controversial new pricing regulations in Canada but industry experts say more is needed.
You may also be interested in...
A delay to implementing drug pricing reforms is an opportunity for Canadian authorities to come up with better proposals, say industry representatives, while authorities remain adamant that action is necessary to lower prices.
Canadian pricing body, the PMPRB, is considering relaxing screening criteria for drugs that will be subject to stricter price controls and extending grace periods for conforming with new rules.
Drug pricing reform in Canada could prompt companies to launch elsewhere or see drugs diverted to the US.